Pharma Focus Asia
KP - Choose our fully recyclable blister films

Novel Ivonescimab (PD-1/VEGF Bispecific Antibody Developed for Non-Small-Cell Lung Carcinoma (NSCLC) patients

Akeso Biopharma developed novel Ivonescimab (PD-1/VEGF bispecific antibody in combination with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) patients.

Novel Ivonescimab is applicable for patients who have failed to respond to prior PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.

Ivonescimab is the first-in-class PD-1/VEGF bi-specific antibody blocking PD-1 binding toPD-L1 and PD-L2 and it also blocks VEGF binding to VEGF receptors. When PD-1 antibody combined with VEGF blocking agents have shown efficient results in different tumors such as renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma.

Ivonescimab, as a single agent can block these two VEGF and PD-1 antibodies and enhance the antitumor activity, compared to combination therapy.

To treat EGFR-mutatedlocally advanced or metastatic NSCLC patients, AK112 is combined with chemotherapy, failed to respond to EGFR-TKI treatment, having completed Phase III clinical trials patient enrollment.

PD-1/L1 monoclonal antibody in combination with platinum-based chemotherapy is the first-line therapy for patients with advanced NSCLC.

AK112 is the only drug candidate approved for NSCLC patients with PD-(L)1 resistant lung cancer treatment in China.

China National Medical Products Administration (NMPA) grants Breakthrough Therapy Designation (BTD) for Ivonescimab (PD-1/VEGFbispecific antibody for Non-Small-Cell Lung Carcinoma (NSCLC).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024